TENX Tenax Therapeutics Inc

0.29
-0.009 (-3.01%)
Last Updated: 13:41:01
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.

Period:

Draw Mode:

Volume 78,743
Bid Price 0.292
Ask Price 0.30
News -
Day High 0.3068

Low
0.25

52 Week Range

High
4.30

Day Low 0.29
Company Name Stock Ticker Symbol Market Type
Tenax Therapeutics Inc TENX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.009 -3.01% 0.29 13:41:01
Open Price Low Price High Price Close Price Prev Close
0.30 0.29 0.3068 0.299
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
133 78,743 $ 0.2962326 $ 23,326 - 0.25 - 4.30
Last Trade Time Type Quantity Stock Price Currency
13:25:16 4,000 $ 0.29 USD

Tenax Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
6.92M 23.86M - 0 -11.05M -0.46 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Tenax Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No TENX Message Board. Create One! See More Posts on TENX Message Board See More Message Board Posts

Historical TENX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.28010.31380.28010.2943896201,0140.00993.53%
1 Month0.34650.35910.2780.3016805229,728-0.0565-16.31%
3 Months0.30050.4274530.2780.3349349534,416-0.0105-3.49%
6 Months0.43980.450.250.3388437687,418-0.1498-34.06%
1 Year3.6124.300.251.622,607,220-3.32-91.97%
3 Years27.6073.600.2516.971,494,505-27.31-98.95%
5 Years97.00127.800.2519.331,079,207-96.71-99.7%

Tenax Therapeutics Description

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com.
Your Recent History
NASDAQ
TENX
Tenax Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now